Ucb Pharma Gmbh

Crozet Medical Gmbh

Rheinische Friedrich-wilhelms-universitat Bonn

Heinrich-heine-universitat Dusseldorf

Ali El-Tayeb

Cécile Pegurier

Joerg Hockemeyer

Christa E Mueller

Marie Ledecq

Laurent Provins

Michael Louis Robert Deligny

Vigneshwaran Namasivayam

Mario Funke

Lukas Schwach

Sabrina Gollos

Joël Mercier

Sanjay Bhattarai

Anaïs Barré

Nader M Boshta

Daniel Von Laufenberg

Jurgen Schrader

Christa Muller

Christa E Müller

Jamshed Iqbal

Larurent Provins

Silvia Lovera

Mahmoud Rashed

Alvaro Cardenas

Nader Boshta

Yong-Qiang Zhang

Jürgen Schrader

Disclosed are N-(phenyl)-1H-indole-3-sulfonanmide and N-(phenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives of formula I substituted at the 1- and 6-positions of the 1H-indole or 1H-pyrrolo[2,3-b]pyridine moiety, as well as structurally related compounds (e.g. the N-pyridin-2-yl and the N-pyridin-3-yl analogues thereof). The present compounds have GPR17 modulating properties which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating disorders such as multiple sclerosis.

N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides

The present invention relates to pyridinyl and pyrazinyl-(aza)indolsulfonamides having GPR17 modulator activity. The compounds have utility in the treatment of a variety of GPR17-associated disorders.

Pyridinyl and pyrazinyl-(asa)indolsulfonamides

A phosphorylated Areceptor agonist providing agonist properties on the Areceptor after dephosphorylation the phosphorylated Areceptor agonist comprises a ribosyl moiety and a purine moiety and being phosphorylated at the 5'-position of the ribose moiety except adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP), a medicament containing the compound of the invention including ADP and the use of the compound of the invention including ATP and ADP for several medical indications e.g. inflammatory events. In particular, compounds of formula (I) are also disclosed. 

Phosphorylated A2A receptor agonists

Growing community of inventors

Bonn, Germany

Ali El-Tayeb